Platelet-Derived Growth Factor Receptors Direct Vascular Development Independent of Vascular Smooth Muscle Cell Function

Wendy J. French, Esther E. Creemers and Michelle D. Tallquist


Updated information and services can be found at: http://mcb.asm.org/content/28/18/5646

These include:

REFERENCES
This article cites 73 articles, 44 of which can be accessed free at: http://mcb.asm.org/content/28/18/5646#ref-list-1

CONTENT ALERTS
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Platelet-Derived Growth Factor Receptors Direct Vascular Development Independent of Vascular Smooth Muscle Cell Function

Wendy J. French, Esther E. Creemers, and Michelle D. Tallquist

Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, and Heart Failure Research Center, University of Amsterdam, Amsterdam, The Netherlands

Received 17 March 2008/Returned for modification 18 April 2008/Accepted 30 June 2008

Complete loss of platelet-derived growth factor (PDGF) receptor signaling results in embryonic lethality around embryonic day 9.5, but the cause of this lethality has not been identified. Because cardiovascular failure often results in embryonic lethality at this time point, we hypothesized that a failure in cardiovascular development could be the cause. To assess the combined role of PDGF receptor α (PDGFRα) and PDGFRβ, we generated embryos that lacked these receptors in cardiomyocytes and vascular smooth muscle cells (VSMC) using conditional gene ablation. Deletion of either PDGFRα or PDGFRβ caused no overt vascular defects, but loss of both receptors using an SM22α-Cre transgenic mouse line led to a disruption in yolk sac blood vessel development. The cell population responsible for this vascular defect was the yolk sac mesothelial cells, not the cardiomyocytes or the VSMC. Coincident with loss of PDGF receptor signaling, we found a reduction in collagen deposition and an increase in MMP-2 activity. Finally, in vitro allantois cultures demonstrated a requirement for PDGF signaling in vessel growth. Together, these data demonstrate that PDGF receptors cooperate in the yolk sac mesothelium to direct blood vessel maturation and suggest that these effects are independent of their role in VSMC development.

Vascular remodeling and maturation are complex processes that transform an endothelial plexus into vessels of various calibers and stabilities. Although angiogenesis has been studied extensively, the mesodermal signals directing these cellular processes are not well understood. One of the first tissues to undergo remodeling during development is the yolk sac, and the proper formation of yolk sac blood vessels is essential for embryonic development and hematopoiesis. Disruption of yolk sac vascular development, either directly or indirectly by aberrant cardiac function, often results in embryonic lethality between embryonic day 9.5 (E9.5) and E11.5 (9). In a majority of cases, the primary cell type responsible for yolk sac vessel abnormalities is the endothelial cell (1). While endothelial cells are commonly implicated in yolk sac phenotypes, the contribution of other yolk sac cell populations should not be discounted. For example, BMP-4 and retinoic acid secretion by the visceral endoderm is required in a paracrine manner for hematopoietic and endothelial development (3, 4, 11, 73), while fibronectin and laminin deposition by the yolk sac mesothelium is required for endothelial remodeling (18).

Due to their close proximity to endothelial cells, vascular smooth muscle cells (VSMC) are also believed to influence blood vessel integrity. In the absence of these support cells, some endothelial vessels are hyperplastic, tortuous, dilated, and leaky (20, 38). In the yolk sac vasculature, it has been difficult to ascertain the function of VSMC because many relevant regulatory molecules are expressed by both endothelial cells and VSMC. Mice that have mutations in transforming growth factor β (TGF-β) signaling exhibit defects in VSMC formation and recruitment, but they also possess cardiovascular and endothelial cell defects (11, 26, 35, 41, 72). Therefore, the lack of VSMC in these mutants may be secondary to aberrant circulation and not the cause of yolk sac vascular demise.

Platelet-derived growth factor (PDGF) receptors have been implicated in cardiovascular development by their functions in cardiac neural crest cells (53, 64), retinal astrocytes (17), mesoderm precursors to endothelial cells (55), VSMC (60), and tumor stroma (50), but few investigations have looked at a role for these receptors in cardiac and yolk sac development. To address this topic, we used Cre/loxP technology to remove PDGF receptors from cardiomyocytes and VSMC. We learned that PDGF receptor expression in the yolk sac mesothelium is essential for yolk sac blood vessel development and that one function of these receptors may be to direct extracellular matrix (ECM) deposition to promote vascular remodeling. These data demonstrate that PDGF receptor function in vascular development may be broader than once thought, and potentially, these receptors may play similar roles in vascular development in other tissues.

MATERIALS AND METHODS

Mouse lines. The mouse lines used in these studies were PDGFRαfl/fl (64), PDGFRαCre (53), Tie2Cre;Her (PDGFRαCre) (23), MoxZCre (65), myocardineGFP (39), Tie2Cre;GFP (30), ROSA26 reporter LacZ (R26R) (61), Tie2GFP (59), and PDGFRαCre (19) lines. SM22α-Cre mice were purchased from Jackson Laboratories. Transgene levels of SM22α-CreTg animals were detected by Southern blot analysis using a probe for the Cre gene. These mice were maintained by inbreeding lines that were homozygous for SM22α-CreTg. Control embryos and yolk sacs were either SM22α-CreTg littermate embryos bearing heterozygous floxed alleles or wild-type embryos (some stage matched). Detection of a vaginal plug was defined as E0.5. PDGFRαCre embryos were recovered up to E18.5, but we recovered fewer than expected after birth. Often, we found postnatal day 1 animals with spina bifida and a cleft palate. Previously, we had determined that the PDGFRα floxed allele is hypomorphic and is lethal in...
combination with a null allele. These data, combined with the fact that myo-
cardin<sup>Cre<sup> can lead to germ line deletion of floxed alleles, suggested that the
lethality was not caused by the conditional deletion of the PDGF receptors but
by loss of PDGFRe signaling regardless of the myo-
cardin<sup>Cre<sup> status of the mice.

**Histology and immunohistochemistry.** Samples stained for b-galactosidase were
fixed in 2% formaldehyde/0.2% glutaraldehyde for 10 min, stained in
streptavidin-biotin (Vector Laboratories, Burlingame, CA) and
sections was performed as previously described (64). Hematoxylin and eosin
peroxidase substrate kit (Vector Laboratories, Burlingame, CA) according to the
manufacturer’s instructions. Antigen retrieval for PECAM and o Scarborough paraffin
sections was performed as previously described (64). Hematoxylin and eosin
(HE) staining and picrosirius red staining were performed according to standard
methods.

**Western blotting and immunoprecipitation.** For immunoprecipitation, whole
yolk sac lysates were incubated overnight at 4°C with 1 l of antibody and then
for 1 h with protein A-Sepharose beads. After being washed, the precipitated
protein were analyzed. Yolk sac lysates were quantified using Bradford reagent, and
proteins were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

**MMP assays.** MMP activity in cell lysates or conditioned media was determined
by incubation in primary antibody for 2 h to overnight at 4°C and visualized using
Alexafluor secondary antibodies or a Vectastain Elite ABC kit and a DAB
peroxidase substrate kit (Vector Laboratories, Burlingame, CA) according to the
manufacturer’s instructions. Antigen retrieval for PECAM and o Scarborough paraffin
sections was performed as previously described (64). Hematoxylin and eosin
(HE) staining and picrosirius red staining were performed according to standard
methods.

**Real-time PCR.** RNA was isolated from yolk sacs using Trizol (Invitrogen,
Carlsbad, CA) and an RNAeasy kit (Qiagen, Valencia, CA). Samples were isolated
and homogenized in Trizol; 20% chloroform was added, mixed well, and cen-
trifuged for layer separation. The top layer was mixed with an equal volume of
70% ethanol, added to an RNAeasy miniprep column, and centrifuged. Washes
were followed according to the RNAeasy protocol and eluted with diethyl pyro-
carbonate-H<sub>2</sub>O. RNA was quantified and DNase treated. RNA (1 l) was used to
generate cDNA using PowerScript reverse transcriptase (Clontech, Mountain
View, CA) and random hexamers. Gene expression was quantified using stan-
dard real-time PCR methods using Sybr green master mixture on an ABI7000
instrument (Applied Biosystems, Foster City, CA). Samples were analyzed in
triplicate on a minimum of three samples per genotype. Primer sequences will be
provided upon request.

**MMP assays.** MMP activity in conditioned media was determined
by incubation with collagenase (Worthington Biochemical, Lakewood, NJ) for
2 h at 37°C in 5% CO<sub>2</sub>. Samples were fixed with 4% PFA for 10 min and stained for
PECAM as described above. Adenovirus transduction was performed using
1 l of medium at the time of plating. PDGF receptor inhibitor (AG1296 [2 l M]; Calbiochem, Gibbstown, NJ) was added to appro-
priate stimulation medium at the time of plating. For collagen 4 assays, wells were
coated for 1 h with 0.5 lg/ml, 5 lg/ml, or 50 lg/ml collagen 4 (R&D
Systems), and then medium was added to the collagen 4 at the time of allantois
plating.

**Image acquisition and manipulation.** Whole-mount and section samples were
analyzed using Nikon SMZ1000 and Zeiss Axiosvert200 (Carl Zeiss,
Thornwood, NY) microscopes. Images were captured using Hamamatsu
Orca-ER (Hamamatsu, Bridgewater, NJ) and Olympus DP71 (Olympus, Center
Valley, PA) cameras with OpenLab 3.5.1 and DP Controller software, respec-
tively. Fluorescent images were colored using OpenLab and then processed in
Adobe Photoshop. Confocal images were captured using an LSM510Meta con-
focal microscope (Carl Zeiss) and processed in ImageJ and Adobe Photoshop.
Color images and Western blots were processed in Adobe Photoshop for a white
background. Quantification and threshold measurements were calculated
through ImageJ. Graphs and statistics were generated using Prism (Graphpad).
The final figures were compiled using Canvas 9.

**RESULTS**

**Generation and survival of PDGF receptor smooth muscle
cell knockout embryos.** Previous data from PDGFRe and
PDGF<sub>B</sub> null embryos indicated that PDGFRe is required for
formation of VSMC and that myocardial development is also
affected (21, 34, 37, 60, 66). Because we wanted to investigate the cell lineages dependent on PDGFRe signal transduction,
we used loxp/Cre technology to generate animals that lacked
PDGFRe in both cardiomyocytes and VSMC. We used two
Cre-expressing mouse lines to accomplish the deletion,
SM22α-Cre<sup>Tg<sup> (23) and myoordin<sup>Cre<sup> (39) lines. SM22α is ex-
pressed as early as E8.5 in cardiomyocyte development and
throughout VSMC terminal differentiation (36), while myoordin
is expressed by E8.5 in cardiomyocytes and is one of the earliest
genes expressed in VSMC precursors (68). Surprisingly, de-
letion of PDGFRe using either SM22αCre<sup>Tg<sup> referred to as
PDGFRe<sup>Tg<sup>) or myoordin<sup>Cre<sup> referred to as PDGFRe<sup>SKO<sup>) mice did not phenocopy PDGFRe<sup>−/−<sup> mice. Both PDGFRe<sup>SKO<sup> and
PDGFRe<sup>SKO<sup> embryos and mice were viable and fertile.

Recently, we have shown that the two PDGF receptors
(PDGFRe and -B) act cooperatively in the neural-crest-de-
derived smooth muscle of the aortic arch (53). To determine if
PDGFRe was compensating for loss of PDGFRe signaling in the
other VSMC populations, we generated mice that contained
SM22α-Cre<sup>Tg<sup> and conditional alleles of both PDGF receptors.
Genotyping of offspring from these crosses revealed that few
PDGFRe<sup>Tg<sup>; PDGFRe<sup>SKO<sup>; SM22α-Cre<sup>Tg<sup> (PDGFRe<sup>SKO<sup>) pups were
recovered at birth, indicating that PDGF receptor signaling
through both receptors was required for viability in an
SM22α-expressing cell population. Using timed matings, we
recovered the expected Mendelian ratios of embryos up to
E10.5 but few PDGFRe<sup>SKO<sup> embryos past that time point. The
few viable mice that were doubly homozygous for the PDGF
receptor floxed alleles were SM22α-Cre<sup>Tg<sup>Cre<sup>Tg<sup> (hemizygous for the
transgene) (data not shown). We surmised that the expres-
sion level of Cre in mice hemizygous for the transgene was not
sufficient to recombine all four floxed alleles efficiently. In-
deed, no PDGFRe<sup>SKO<sup> pups resulted from breeders that were
SM22α-Cre<sup>Tg<sup>Tg<sup>Cre<sup>Tg<sup>Cre<sup>Tg<sup>. All subsequent analyses were performed us-
ing mice homozygous for SM22α-Cre<sup>Tg<sup>. Commonly, transgenic
Cre lines are not maintained as homozygotes due to potential
transgene insertion effects. We have ruled out these effects,
because lethality occurs only in double-homozygous PDGF
receptor SM22α-Cre<sup>Tg<sup>Tg<sup>Cre<sup>Tg<sup> embryos, not single PDGF receptor
SM22α-Cre<sup>Tg<sup>Tg<sup>Cre<sup>Tg<sup> embryos. Because SM22α-Cre<sup>Tg<sup> was likely to
target deletion in VSMC similarly to myocardinCre, we predicted that excision of the two PDGF receptor genes in this mouse line (PDGFRMKO) would phenocopy the embryonic lethality observed in PDGFRSKO embryos. However, PDGFRMKO embryos survived until birth.

Expression of SM22-Cre before VSMC differentiation in the yolk sac. The dramatic difference in survival between PDGFRSKO and PDGFRMKO embryos led us to investigate the profiles of Cre activity in the two Cre mouse lines. Using ROSA26 reporter mice, we determined SM22α-Creβ and myocardinCre expression between E8.5 and E10.5. Cre activity was not detected in any tissue at E7.5 using either of the Cre lines. By E8.5, SM22α-Cre activity was observed in many cells of the yolk sac, as well as a small number of cells in the primitive heart (Fig. 1A). In contrast, myocardin-Cre activity was detected in the cardiac crescent, and only a few β-galactosidase-positive cells were observed in myocardinCre yolk sacs (Fig. 1E). Because Cre expression in the yolk sac was the most obvious difference between these lines, we examined histological sections of this tissue. At E8.5, SM22α-Cre activity was present throughout the yolk sac mesothelium, but no β-galactosidase-positive cells were detected in the myocardinCre yolk sacs (Fig. 1A and E). The yolk sac mesothelium is a mesoderm-derived epithelium-like component of the yolk sac that rests on a thin basement membrane and is believed to be important for transport and movement of fluid from the yolk sac. At E9.5, β-galactosidase-positive cells were present both in the mesothelial layer and surrounding some vessels in the SM22α-Creβ mice, while myocardinCre activity was present in only a few cells associated with blood vessels, presumably VSMC progenitors (Fig. 1B and F). At E10.5, SM22α-Creβ and myocardinCre yolk sacs both possessed β-galactosidase expression in cells surrounding blood vessels, but β-galactosidase expression in myocardinCre was lacking in yolk sac mesoderm populations that were not vessel associated (Fig. 1C and G). These data pointed to the possibility that deletion of the PDGF receptors in the yolk sac mesothelium caused the embryonic lethality.

Because Cre expression leads to indelible β-galactosidase expression, we could also use this marker to follow mesothelial and VSMC cell lineages in PDGFRSKO and PDGFRMKO embryos. In both PDGFRSKO and PDGFRMKO yolk sacs, few perivascular, β-galactosidase-positive cells were present at E10.5 (Fig. 1D and H). β-Galactosidase-positive cells were abundant in the mesothelial layer in the PDGFRSKO yolk sac, demonstrating that loss of PDGF receptors did not lead to failure in the formation of this cell population. In addition, examination of both PDGFRSKO and PDGFRMKO embryos revealed abundant β-galactosidase-positive cells in the hearts and trunk areas (data not shown), demonstrating that loss of the receptors did not result in a general reduction of mesoderm cells.

PDGFRα and PDGFRβ are coexpressed in the yolk sac mesothelium and perivascular cells. While PDGFRα and PDGFRβ expression has been documented as early as E6.5 in the extraembryonic endoderm and ectoplacental cone, and the ligands are expressed in the chorionic ectoderm and parietal endoderm (42, 48, 58), analysis of coexpression of the receptors in the yolk sac has not been done. Therefore, we investigated the expression patterns of the receptors. Expression of PDGFRα was detected using mice that expressed a nuclear-localized GFP from the PDGFRα locus that faithfully traced PDGFRα expression (19) and a PDGFRβ-specific antibody. At E8.5, PDGFRα and PDGFRβ were expressed in the mesothelium and endoderm, as previously reported (Fig. 2A). At E9.5, PDGFRβ endoderm expression was reduced, but expression of both receptors was maintained in the mesothelium (Fig. 2B and data not shown). At E10.5, both receptors were expressed in the mesothelium, but only PDGFRβ was identified in cells surrounding endothelial vessels (Fig. 2C). Presumably,
these cells were VSMC. The early and persistent coexpression of PDGF receptors in the mesothelial layer (Fig. 2D), along with lethality of PDGFR$^{SKO}$ but not PDGFR$^{MKO}$, supports the possibility that PDGF receptor expression in the mesothelium is required for embryo viability.

Because multiple reports have suggested that PDGFR$\beta$ is expressed by endothelial cells and to further refine our expression analysis in the yolk sac, we examined PDGFR$\beta$ expression in Tie2GFP$^+$ mice. These mice express GFP in endothelial cells (59). We found no Tie2-positive cells that expressed detectable levels of PDGFR$\beta$ between E8.0 and E10.5 (Fig. 2E and data not shown). Tie2GFP$^+$ cells were present in blood islands adjacent to PDGFR$\beta$-expressing mesothelium at E8.5. This expression profile was consistent with a previous report that demonstrated PDGFR$\beta$ expression in mesoderm precursors in the yolk sac but not in differentiated endothelial cells (55).

**PDGFR$^{SKO}$ results in incomplete yolk sac capillary bed reorganization.** Embryonic lethality between E9.5 and E10.5 is often a result of cardiovascular failure, but αSMA staining for cardiomyocytes and PECAM staining for endothelial cells revealed that cardiac and embryonic vascular development appeared normal in E10.5 PDGFR$^{SKO}$ embryos (Fig. 3A to D). No cardiovascular defects were observed in the embryo proper. This lack of a cardiomyocyte phenotype is in agreement with gene deletion analysis of PDGF receptors using an early mesoderm-expressed Cre line, MesP1Cre (27). By contrast, whole-mount views and histological sections of PDGFR$^{SKO}$ embryos at E10.5 revealed an apparent cessation of blood vessel maturation within the yolk sac (Fig. 3E and F). While endoderm and mesothelial layers appeared normal, endothelial vessels were distended and disorganized compared to vessels in control embryos. At this time point, we also observed efficient deletion of both PDGFR$\alpha$ and PDGFR$\beta$ in PDGFR$^{SKO}$ yolk

![Image of PDGFR$\beta$ expression in yolk sac mesothelium](image.png)
sacs (Fig. 3G and H). Analyses of E9.5 and E10.5 mutant yolk sacs indicated no abnormalities in proliferation by bromodeoxyuridine incorporation, and at the same time points, we observed no increase in apoptotic cells, as determined by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling in situ (data not shown).

To assess yolk sac vascular development in our mutants, we performed whole-mount PECAM staining. Vasculogenesis of the yolk sac begins at E7.5, and a number of signaling proteins have been implicated in the process (1). After E8.5, yolk sac vessels undergo a dramatic remodeling event in which the primitive polygonal structure of the vasculature is converted to stable and defined vessels (15). In both control and mutant yolk sacs, we observed the typical honeycomb pattern of endothelial cells at E9.5 (Fig. 4A and B), but at E10.5, PDGFR<sup>SKO</sup> yolk sacs retained the characteristics of an immature yolk sac and failed to reorganize into the normal hierarchical array of large and small vessels (Fig. 4G).

To establish if these yolk sac defects were caused primarily by loss of one of the receptors, we analyzed yolk sac vessels by PECAM staining in single PDGF receptor mutants. Yolk sacs from PDGFR<sub>α</sub><sup>−/−</sup>, PDGFR<sub>β</sub><sup>−/−</sup>, PDGFR<sub>α</sub>SKO, and PDGFR<sub>β</sub>SKO mutants developed normally, although the remodeled vessels in the E10.5 PDGFR<sub>β</sub><sup>−/−</sup> yolk sacs were slightly more disorganized than control vessels (Fig. 4D, I, and J and data not shown). We next analyzed embryos with complete deletion of both receptors to determine if this genotype would phenocopy the PDGFR<sub>SKO</sub> embryos. To increase the probability of obtaining double-mutant embryos, we crossed our conditional animals with Meox<sup>2<sup>Cre</sup></sup> mice. Meox<sup>2<sup>Cre</sup></sup> expresses Cre in all embryonic tissues and the extraembryonic mesoderm (65). Many of the mutant embryos were being resorbed by E9.5, consistent with the phenotype of PDGF receptor double-homozygous embryos (M. D. Tallquist, unpublished observation), but a few embryos were recovered. They exhibited a complete failure in yolk sac remodeling (PDGFR<sub>Meox<sup>Cre</sup></sub>) (Fig. 4E) that resembled the hyperfusion phenotype described previously (12, 13), providing further evidence that loss of both PDGF receptors results in yolk sac vascular abnormalities.

**Loss of PDGF receptors results in an increase of endothelial gene expression.** Vascular remodeling is controlled by activities of multiple cell populations, including endothelial (15) and mural (57) cells. To examine the differentiation status of these cell populations, we analyzed yolk sac gene expression by real-time PCR. First, expression analysis demonstrated an expected decrease in PDGFR<sub>α</sub> and PDGFR<sub>β</sub> in the SM22α-Cre<sup>Tg</sup> mutants compared to wild-type yolk sacs (Fig. 5A). Consistent with results from Hand1 mutants (45), another yolk sac remodeling mutant, we observed enhanced expression of endothelial receptors, such as VEGFR1 (Flt1), VEGFR2 (Flk1), and Tie2 (Fig. 5B). Levels of endothelial-cell-specific genes, VEGF, PDGFB, and VE cadherin, were not significantly different between mutant and control samples (Fig. 5B). Nonetheless, elevated levels of endothelial receptors in PDGFR<sub>SKO</sub> yolk sacs suggested that impaired vascular development might be inducing an enhanced but nonproductive angiogenic response.

To rule out a direct requirement for PDGF receptors in endothelial cells, we generated embryos that lacked all PDGF receptor expression in endothelial cells using a Tie2Cre<sup>Tg</sup>
mouse line (PDGFR<sup>EKO</sup>) (30). We recovered viable PDGFR<sup>EKO</sup> mutants at E12.5 and E15.5, and no obvious defects were observed in yolk sac development (data not shown). Together, these data imply that PDGF receptor signaling is not employed by endothelial cells and that the remodeling phenotype is caused by loss of the receptors in either VSMC or the mesothelium.

The remodeling defect is not caused by loss of PDGF receptor signaling in VSMC. We next examined the expression of VSMC genes in the PDGFR<sup>SKO</sup> yolk sacs. Consistent with the lack of VSMC we observed by lineage tracing (Fig. 1D), VSMC gene expression was reduced. Expression of the gene encoding myocardin-related transcription factor B (MRTFB), a yolk sac smooth muscle transcription factor (70), was reduced in PDGFR<sup>MKO</sup> yolk sacs. (F to K) Yolk sac vascular remodeling progression to large defined vessels visualized by PECAM staining. PDGFR<sup>SKO</sup> yolk sacs fail to undergo vascular remodeling, resembling the E9.5 yolk sac vascular plexus. (L to Q) αSMA staining was used to detect VSMC at E10.5 on the indicated genotypes. Recruitment of VSMC to developing vasculature present in control E10.5 yolk sacs is severely decreased intensity and thickness of collagen. In contrast, PDGFR<sup>MKO</sup> yolk sacs and absent in PDGFR<sup>SKO</sup> and PDGFRβ<sup>+/−</sup> yolk sacs. The images represent similar regions of the yolk sac adjacent to, but not including, the vitelline vessels. The images are representative of a minimum of three yolk sacs of each genotype. Scale bars = 10 μm.

FIG. 4. Vascular development is disrupted in PDGFR<sup>SKO</sup> yolk sacs but not in single mutants. (A to E) Whole-mount E9.5 yolk sac staining for PECAM on the indicated genotypes. A normal vascular plexus was observed in control, PDGFR<sup>SKO</sup>, PDGFR<sup>MKO</sup>, and PDGFRβ<sup>−/−</sup> yolk sacs, but it was disrupted in PDGFR<sup>Mox2</sup> yolk sacs. (F to K) Yolk sac vascular remodeling progression to large defined vessels visualized by PECAM staining. PDGFR<sup>SKO</sup> yolk sacs fail to undergo vascular remodeling, resembling the E9.5 yolk sac vascular plexus. (L to Q) αSMA staining was used to detect VSMC at E10.5 on the indicated genotypes. Recruitment of VSMC to developing vasculature present in control E10.5 yolk sacs is severely reduced in PDGFRβ<sup>SKO</sup>, PDGFR<sup>MKO</sup>, and PDGFR<sup>Mox2</sup> yolk sacs and absent in PDGFR<sup>SKO</sup> and PDGFRβ<sup>−/−</sup> yolk sacs. The images represent similar regions of the yolk sac adjacent to, but not including, the vitelline vessels. The images are representative of a minimum of three yolk sacs of each genotype. Scale bars = 10 μm.

These expression data suggested a disruption in the VSMC population. Therefore, we examined E10.5 control, PDGFR<sup>SKO</sup>, and PDGFR<sup>MKO</sup> yolk sacs for the presence of VSMC. While the control yolk sacs had extensive networks of vessels that contained αSMA-positive cells, in both mutant yolk sac genotypes, few αSMA-expressing cells were present next to endothelial vessels compared to control yolk sacs (Fig. 4L to N). This result suggested that PDGF receptor signaling was required for VSMC formation. To identify if a specific receptor was important for VSMC formation, we examined αSMA staining in null and conditional mutants for PDGFRα and PDGFRβ individually (Fig. 4 and data not shown). In PDGFRβ<sup>−/−</sup> and PDGFRβ conditional deletion lines, loss of PDGFRβ led to a dramatic reduction in yolk sac VSMC (Fig. 4O to Q). However, despite the lack of VSMC in these mutants, the yolk sac vasculature was organized into vessels of different calibers. These data suggest that PDGFRβ may be the essential PDGF receptor involved in VSMC development in the yolk sac. However, the presence of normal vessel remodeling in the absence of VSMC indicated that the yolk sac phenotype we observed in PDGFR<sup>SKO</sup> yolk sacs was not caused by a failure of VSMC association. The mesothelial cells were therefore implicated as the primary cell population responsible for this phenotype, as they were the only yolk sac cells that expressed Cre in SM22α-Cre<sup>Tg</sup> conditional mutants that did not express Cre in myocardin<sup>Cre</sup> conditional mutants.

PDGF receptor signaling affects ECM deposition. Mesothelial cells have a number of proposed functions, including transport of fluids, production of growth factors, and secretion of ECM. Because the vascular defects we observed resembled retinoic acid and TGF-β signaling pathway mutants that are deficient in ECM production (3, 7, 18), we examined the distribution of ECM in wild-type, PDGFR<sup>SKO</sup>, and PDGFR<sup>MKO</sup> yolk sacs. Staining for fibrillar collagen with picrosirius red (Fig. 6A) demonstrated that PDGFR<sup>SKO</sup> yolk sacs had a decreased intensity and thickness of collagen. In contrast, PDGFR<sup>MKO</sup> yolk sacs appeared similar to wild-type samples. Immunohistochemistry for collagen 1 and collagen 4 in PDGFR<sup>SKO</sup> yolk sacs supported the picrosirius red findings.
The reduction in collagens was limited to the mesothelium, as collagen 4 was detected in close proximity to the endothelial cells. In contrast, fibronectin and laminin appeared relatively unperturbed at this stage (Fig. 6D and E). To determine if the reduction in collagen was at the transcriptional level, we performed real-time PCR analysis. We detected only modest changes in transcript levels of collagens and fibronectin (Fig. 6F).

Because collagen synthesis was only moderately affected, we investigated other processes that would explain a reduction in collagen protein levels. One candidate mechanism was an increase in MMP activity. MMPs are a family of proteinases that are capable of degrading a wide variety of ECM proteins. When we examined yolk sacs using an MMP in situ assay, we detected increased MMP activity in mutant mesothelium compared to controls (Fig. 6G). Similarly, gelatin zymography consistently demonstrated higher levels of activated MMP-2 in PDGFRSKO mutant yolk sacs than in control yolk sacs (Fig. 6H). Taken together, these data suggest that PDGF receptor signaling from the mesothelium may function to direct blood vessel remodeling in part by controlling the degradation of matrix in the yolk sac.

**PDGF receptor signaling controls blood vessel morphogenesis.** To further examine the role of PDGF receptors in vascular development, we used an allantois culture assay. E8.5 allantoides from wild-type embryos develop rudimentary vascular structures, but when stimulated with either 10% FBS or PDGFBB, a ligand that can activate both PDGFRα and PDGFRβ, the vascular plexus expands (Fig. 7A and C). In addition, we showed that PDGF receptor signaling in these cultures was required for stabilization of the vessels. Using a Cre-expressing adenovirus, we were able to induce recombination in allantois explants from embryos homozygous for both PDGFRα and PDGFRβ floxed alleles (PDGFRfl/fl). When both PDGF receptors were deleted using Cre, vascular expansion was severely reduced (Fig. 7B and C). Quantification of vascular expansion demonstrated that PDGF receptor stimulation yielded cultures that were comparable to those produced by serum stimulation (Fig. 7C). Similarly, addition of a PDGF receptor-specific inhibitor (AG1296) to the cultures resulted in a lack of vascular expansion similar to that of unstimulated cultures (Fig. 7D). We could not examine the effects of the PDGF receptor inhibitor on PDGFBB-stimulated cultures, as these cultures did not adhere to the coverslip. To determine the effect of exogenous addition of matrix, we plated allantois cultures on collagen 4 and found that exogenous collagen 4 resulted in increased vascular expansion in 1% serum. Treatment with collagen 4 was even capable of bypassing the effects of PDGF inhibition on cultures stimulated with either 10% FBS or PDGFBB (Fig. 7D and data not shown).

Finally, to examine how reduced ECM could affect endothelial cell signaling, we determined if integrin function within the yolk sac was disrupted. To accomplish this, we examined the activation status of integrin β1. Integrin β1 is essential for endothelial cell function (5) and is one of the key integrins in endothelial cell morphogenesis. Phosphorylation of integrin β1 on S785 modulates cell adhesion and migration. Using a phosphospecific antibody for S785 of β1 integrin (46), we found that phosphorylation on S785 was reduced, even though levels of β1 integrin were similar in control and PDGFRSKO yolk sacs (Fig. 7E). Taken together, these data suggest that loss of PDGF receptor signaling leads to reduced vascular remodeling that may be related to a loss of matrix integrity.

**DISCUSSION**

The generation of mature blood vessels requires coordination between endothelial cells and their surrounding tissues. While it is established that growth factor secretion and guidance cues are necessary for appropriate vessel patterning,
many of the processes involved in directing vessel remodeling remain a mystery. Here, we have shown that one of the signals required in yolk sac vessel formation derives from PDGF receptor signals in the mesoderm. By deleting the receptors from select cell populations, we showed that PDGF signaling is required for vascular remodeling. Unexpectedly, we observed normal progression of vasculogenesis in the absence of VSMC, suggesting that vascular remodeling is not due to a failure of VSMC formation. Instead, PDGF receptors in the extraembryonic mesoderm provide signals for yolk sac vascular progression.

The origin of VSMC in the yolk sac is currently unclear, but there are two potential sources. One is from embryonic hemangioblasts that arise in the primitive streak and migrate to the yolk sac to form the blood islands. Clonal analysis of *brachyury*-positive and *VEGFR2*-positive cells has suggested that a single progenitor can give rise to endothelial and hematopoietic cells and VSMC (14, 24). Another possibility is that the yolk sac VSMC arise from the yolk sac mesothelium. Evidence is accumulating to suggest that the mesothelium can differentiate into components of blood vessels, including VSMC and fibroblasts. The heart was the first tissue identified in which the mesothelium (epicardium) differentiates and contributes to the vascular structures (10, 43, 44, 67). Others have shown more recently that the serosal mesothelium can also contribute to the VSMC of the gut (29, 71). Interestingly, stimulation of either tissue by PDGFBB results in an increase in VSMC differentiation (29, 40). Although the current re-

FIG. 6. ECM deposition disruption along the mesothelium. (A) Picrosirius red staining of paraffin sections of E10.5 yolk sacs demonstrating *PDGFR<sup>SKO</sup>* yolk sac reduction in collagen compared to control and *PDGFR<sup>MKO</sup>* yolk sacs. (B to E) Immunohistochemistry of E10.5 control, *PDGFR<sup>SKO</sup>* and *PDGFR<sup>MKO</sup>* yolk sac sections for detection of ECM molecule expression as indicated. (F) Quantitative PCR gene expression analysis for matrix molecules in control and *PDGFR<sup>SKO</sup>* E10.5 yolk sacs. Individual symbols and mean bars represent each sample analyzed in triplicate for the wild type (WT) and SKO mutants. Student *t* test: *, *<0.15. (G) E10.5 fresh-frozen yolk sac sections of control and *PDGFR<sup>SKO</sup>* mutants imaged for MMP activity observed through increasing levels of fluorescence detected by in situ DQ gelatin assay. (H) Gelatin zymography demonstrating increased MMP2 activity in *PDGFR<sup>SKO</sup>* E10.5 whole yolk sac lysates compared to control lysates. The arrowheads indicate mesothelial loss of collagen 1 and collagen 4. The asterisks indicate blood vessels. ee, extraembryonic endoderm; mes, mesothelium. Scale bars = 40 μm.
agents do not permit us to conclusively prove the origin of yolk sac VSMC, our data are consistent with the possibility that the yolk sac mesothelium can give rise to perivascular cells. Loss of PDGF receptors in the SM22α-Cre transgenic line leads to an early absence of VSMC. Thus, the mesothelium could be a source of perivascular cells that stabilize the vessels, as well as a source of growth factors and ECM to direct vascular remodeling.

In addition to the uncertainty of VSMC origin, there has also been a longstanding debate over the importance of VSMC in the yolk sac. Disruption of myocardin, an SRF transcriptional cofactor and key regulator of VSMC development, leads to embryonic lethality at E9.5 (69), but it is unclear if this phenotype is caused by loss of VSMC in the yolk sac (51). MRTFβ mutant embryos (MRTFB is a second member of the myocardin family of transcription factors) display a reduction in yolk sac VSMC, but these embryos survive past E10.5, when many mutants with yolk sac phenotypes perish (47, 70). Often, the difficulty in interpreting known yolk sac phenotypes is that many of the genes are likely to affect yolk sac development by multiple avenues. For example, both endothelial cell differentiation and cardiac function are essential for proper yolk sac vessel maturation. Mutations in multiple components of the TGF-β signaling pathway demonstrate dramatic yolk sac vascular disruptions, but these defects could be caused by a failure in endothelial cell or VSMC function (2, 11, 25, 35, 49, 72).

Studies of PDGFRβ- and PDGFB-null embryos have established that a subset of VSMC, sometimes referred to as pericytes, require PDGFRβ signal transduction (21, 38, 60). The loss of PDGFRβ seems to predominantly affect VSMC of smaller vessels, while VSMC of larger vessels, such as the aorta, are less disrupted. Here, we have shown that yolk sac VSMC are dependent on PDGFRβ expression. In multiple mouse lines, loss of PDGFRβ leads to a severe reduction in VSMC of the yolk sac. Surprisingly, endothelial cells in our mutants continued to mature into hierarchical vessels, and early embryogenesis was undisturbed. The only abnormality caused by loss of VSMC was an increase in vessel tortuosity. Our data demonstrate that the yolk sac vasculature does not require VSMC for stability, possibly because the hemodynamic forces within these vessels are not excessive.

Although it is commonly assumed that the two PDGF receptors direct similar cellular responses, there are few in vivo examples of the abilities of these receptors to compensate for each other. This fact is underscored by the disparate phenotypes of the individual receptor knockouts. PDGFRα-null embryos die between E10.5 and E15.5 due to a wide range of defects (62), while PDGFRβ-null embryos die perinatally from

FIG. 7. PDGF receptor signaling in allantois cultures. (A) PECAM staining of E8.5 wild-type allantoides grown in culture for 24 to 26 h with stimulation: 1% FBS, 20 ng PDGFBB, or 10% FBS. (B) PECAM staining of adenovirus Cre-treated E8.5 wild-type or PDGF receptor conditional (PDGFRβfl/fl) allantoides demonstrating that the deletion of PDGF receptor disrupts vasculogenesis in response to PDGFBB and 10% FBS. The insets represent threshold images of PECAM fluorescence that were used to quantify the vascular area. (C) Quantification of vasculogenesis in the allantois assays by measurement of PECAM staining in stimulated and unstimulated samples in the presence or absence of PDGF receptor expression. (D) Quantification of PECAM staining in the presence of a PDGF receptor inhibitor (AG1296) and increasing concentrations of collagen 4 compared to 10% FBS. (E) E10.5 yolk sac lysates immunoprecipitated for integrin β1 and analyzed for activation by Western blot analysis for phosphorylation of integrin β1 at S785 and integrin β1 demonstrating decreased phosphorylation yet similar levels of integrin β1. Student t test: *, <0.07; ***, <0.005. Scale bars = 20 μm. Red, PECAM; blue, DAPI.
vascular defects (60). However, in the yolk sac, we found that if one of the receptors was expressed, blood vessel remodeling occurred normally. The observed redundancy in the yolk sac mesoderms leads to the possibility that the PDGF receptors may contribute to vessel remodeling in other tissues. Another example of receptor cooperativity in vessel remodeling was observed in cardiac neural crest cells. When PDGF receptors are removed from neural crest cells, failure of aortic arch vessel remodeling leads to persistent truncus arteriosus (53). Because PDGFβR/β-null embryos die before E10.5, this general requirement for PDGF receptor signaling and vascular remodeling may have been overlooked.

ECM disruptions have been found in several mouse mutants with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects (60). However, in the yolk sac, we found that the yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibronectin, and laminin expression have demonstrated vascular defects with yolk sac phenotypes. Mutations in collagen 4, fibro...


